netFormulary
 Report : A-Z HCD items in Formulary 22/10/2020 15:46:27
[Back]
 
Section Status BlueTeq Name
08.03.04.02 Formulary BlueTeq Abiraterone Zytiga®
08.01.05 Formulary BlueTeq Alectinib Alecensa®
08.02.03 Formulary BlueTeq Alemtuzumab Lemtrada®
08.01.05 Formulary BlueTeq Arsenic Trioxide Trisenox®
08.02.04 Formulary BlueTeq Atezolizumab  (Tecentriq®)
08.02.04 Formulary BlueTeq Avelumab  (Bavencio®)
08.02.04 Formulary BlueTeq Axicabtagene ciloleuce (Yescarta®)
08.01.01 Formulary BlueTeq Bendamustine 
08.01.05 Formulary BlueTeq Bevacizumab Avastin®
08.02 Formulary BlueTeq Blinatumomab Blincyto®
08.01.05 Formulary BlueTeq Bortezomib Velcade®
08.01.05 Formulary BlueTeq Bosutinib Bosulif®
08.01.05 Formulary BlueTeq Cabazitaxel Jevtana®
08.01.05 Formulary BlueTeq Carfilzomib Kyprolis®
08.01.05 Formulary BlueTeq Ceritinib Zykadia
08.01.05 Formulary BlueTeq Cetuximab Erbitux®
08.01.03 Formulary BlueTeq Clofarabine Evoltra®
08.01.05 Formulary BlueTeq Crizotinib Xalkori®
08.01.05 Formulary BlueTeq Dacomitinib Vizimpro®)
08.02.04 Formulary BlueTeq Daratumumab  (Darzalex®)
08.01.05 Restricted Use BlueTeq Dasatinib Sprycel®
08.02.04 Formulary BlueTeq Dinutuximab  (Qarziba®)
08.01.02 Formulary BlueTeq Doxorubicin Caelyx®
08.02.04 Formulary BlueTeq Durvalumab   (Imfinzi® )
08.01.05 Formulary BlueTeq Eribulin Halaven®
08.01.05 Restricted Use BlueTeq Everolimus Afinitor®
08.02.04 Formulary BlueTeq Glatiramer Acetate Copaxone®
05.03.03.02 Formulary BlueTeq Glecaprevir and Pibrentasvir Maviret®
08.02.04 Formulary BlueTeq Immunocellular therapy containing tisagenlecleucel, autologous T cells genetically modified ex vivo using a lentiviral vector encoding an anti-CD19 chimeric antigen receptor (CAR) (Kymriah®)
08.01 Formulary BlueTeq Inotuzumab ozogamicin Besponsa®
08.02.04 Formulary BlueTeq Interferon Beta Avonex®
08.02.04 Formulary BlueTeq Interferon Beta Rebif®
08.02.04 Formulary BlueTeq Interferon Beta Betaferon®
08.01.05 Formulary BlueTeq Ipilimumab Yervoy®
08.01.05 Formulary BlueTeq Larotrectinib  
08.02.04 Formulary BlueTeq Lenalidomide 
08.01.05 Formulary BlueTeq Lenvatinib Lenvima® and Kisplyx®
08.01.05 Formulary BlueTeq Lorlatinib  
08.01.05 Formulary BlueTeq Midostaurin Rydapt®
08.02.04 Formulary BlueTeq Natalizumab Tysabri®
08.01.03 Formulary BlueTeq Nelarabine Atriance®
08.02.04 Formulary BlueTeq Niraparib (Zejula®)
08.02.04 Formulary BlueTeq Nivolumab Opdivo®
08.02.03 Formulary BlueTeq Obinutuzumab Gazyvaro ®
08.02.04 Formulary BlueTeq Osimertinib Tagrisso
08.01.05 Formulary BlueTeq Paclitaxel - Albumin Bound Formulation Abraxane®
05.03.05 Restricted Use BlueTeq Palivizumab Synagis®
08.01.05 Formulary BlueTeq Pembrolizumab Keytruda®
08.02.04 Formulary BlueTeq Pemrolizumab Keytruda®
08.01.05 Formulary BlueTeq Pertuzumab Perjeta®
08.02.04 Formulary BlueTeq Pomalidomide Imnovid®
08.01.05 Formulary BlueTeq Regorafenib Stivarga®
05.03.05 Formulary BlueTeq Ribavirin 
08.01.05 Formulary BlueTeq Ribociclib 
08.02.03 Formulary BlueTeq Rituximab MabThera®Truxima ®
05.03.03.02 Formulary BlueTeq Sofosbuvir, Velpatasvir and Voxilaprevir Vosevi®
08.01.05 Formulary BlueTeq Sorafenib Nexavar®
08.01.05 Formulary BlueTeq Sunitinib Sutent®
08.02.04 Formulary BlueTeq Talimogene laherparepvac Imlygic®
08.02.04 Formulary BlueTeq Teriflunomide Aubagio®
08.01.05 Formulary BlueTeq Tivozanib (Fotivda®)
08.01.05 Formulary BlueTeq Trametinib Mekinist®
08.01.05 Formulary BlueTeq Trastuzumab Herceptin®
08.01.05 Formulary BlueTeq Trastuzumab emtansine Kadcyla®
08.01.05 Formulary BlueTeq Trifluridine and Tipiracil  Lonsurf ®
08.01.05 Formulary BlueTeq Venetoclax Venclyxto ®
Northern Lincolnshire